Preoperative aspirin and major perioperative outcomes in patients with
hypertension undergoing cardiac surgery
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Introduction

Results

Discussion

• Hypertension is prevalent in patients undergoing cardiac
surgery and associated with a higher incidence of
cardiovascular complications.

• The aspirin group of hypertensive patients had significantly
higher rates of comorbidities including diabetes mellitus,
peripheral vascular disease, and previous myocardial infarction
compared to the non-aspirin group.

• Preoperative aspirin therapy is associated with a significant
decrease in the risk of MACEs, postoperative renal failure,
prolonged ICU stay, and 30-day mortality, but does not increase
the risk of readmissions in patients with hypertension
undergoing cardiac surgery.

• Aspirin has been shown to prevent cardiovascular events in
patients with a high risk of cardiovascular disease.
• Very few studies have investigated aspirin and hypertension,
particularly its effects on major outcomes in hypertensive
patients undergoing cardiac surgery.1,2

Objective
• To determine the effects of preoperative aspirin on
postoperative outcomes for patients with hypertension
undergoing cardiac surgery.
• To examine the impact of chronic kidney disease and heart
failure superimposed with hypertension on outcomes after
cardiac surgery.

• Among 3,290 patients:
• 71.2% were taking aspirin preoperatively.
• 28.8% were not.
• With propensity score adjustment and multivariate logistic
regression, this study showed that preoperative aspirin in
hypertensive patients undergoing cardiac surgery significantly
reduced the risk of (Figure 1, Table 1):

• This indicates, for the first time, that preoperative aspirin is
beneficial for hypertensive patients undergoing cardiac surgery.
• In addition, hypertensive patients with superimposed CKD or
heart failure are at an increased risk of mortality following
cardiac surgery compared to patients with hypertension alone.

• 30-day mortality (3.7% vs 6.8%, P = 0.006)
• postoperative renal failure (4.2% vs 8.0%, P < 0.001)
• prolonged ICU stay (mean 109.1 vs 133.7 h, P < 0.001)
• MACEs (9.1% vs 12.7%, P = 0.046)
• There was no significant difference in readmissions between the
two groups.
• In addition to hypertension, 13.6% of patients had heart failure
and 15.1% had CKD.

Methods
• Retrospective cohort study.
• 6,514 consecutive patients from two tertiary hospitals
undergoing cardiac surgery from 2001 to 2014, including:
• Coronary artery bypass graft (CABG), valve surgery,
CABG plus valve surgery, and other cardiac surgery
• 3,290 patients had hypertension and met inclusion criteria;
they were divided into two groups:
• With preoperative aspirin or without (control).
• Patients were also divided into three groups based on the
presence of additional comorbidities:
• Hypertension plus heart failure (HHF), hypertension
plus chronic kidney disease (HCKD), or hypertension
without heart failure or CKD (HTN).
• Outcomes include:
• Major adverse cardiocerebral events (MACE), 30-day
mortality, renal failure, intensive care unit (ICU) stay,
and readmission.
v CKD, defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2
v MACE includes perioperative myocardial infarction (MI), heart block, cardiac arrest,
permanent stroke, transient ischemic attack, coma, and renal failure.

• Overall, there was a tendency toward unfavorable outcomes in
patients with heart failure and CKD (Table 2):
• 30-day mortality rates were 4.1%, 4.8%, and 7.1% in the
HTN, HCKD, and HHF group respectively.

Table 2. Postoperative complciations and mortality in hypertension patients undergoing
cardiac surgery
OUTCOME
HTN
HCKD
HHF
P
MACE
9.8% (238)
9.7 % (48)
12.2% (55)
0.279
106.32 ± 172.79
123.95 ± 192.28
166.78 ± 266.38
<0.001
Total Hrs ICU (h)
Readmission
13.6% (330)
14.5% (72)
17.4% (78)
0.114
30-Day Mortality
4.1% (100)
4.8% (24)
7.1% (32)
0.021
Notes: HTN, hypertension without heart failure or chronic kidney disease; HCKD,
hypertension with chronic kidney disease; HHF, hypertension with heart failure. Among
patients with HCKD and HHF, 74 had both heart failure and chronic kidney disease.

Table 1. Effects of aspirin on postoperative complications and mortality in hypertension patients undergoing
cardiac surgery.
Preoperative aspirin
OUTCOME
Yes (2342)
No (948)
9.1% (213)
12.7% (122)
MACE
Renal Failure
4.2% (99)
8.0% (76)
Total Hrs ICU (h) 109.11 ± 164.77 133.65 ± 223.16
Readmission
14.6% (343)
13.5% (128)
30-Day Mortality
3.7% (86)
6.8% (64)

Univariate
OR (95% CI)
0.677 (0.535 - 0.858)
0.506 (0.372 - 0.690)
1.099 (0.883 - 1.368)
0.527 (0.377 - 0.734)

Adjusted
P
P
OR (95% CI)
0.001 0.765 (0.589 - 0.995) 0.046
<0.001 0.570 (0.404 - 0.805) 0.001
<0.001
0.396 1.126 (0.887 - 1.431) 0.329
<0.001 0.593 (0.408 - 0.863) 0.006
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